Impressive results for Anito-Cel new BCMA-targeted CART for #myeloma after median 4 prior lines of Rx. Proud that the #Karmanos Cancer Institute’s Dr Abhinav Deol was a co-investigator. This CART now in Phase 3 trial

BCMA/GPRC5D-dual targeting CART for relapsed #myeloma. The usual CART toxicity, decent response rates, and somehow no skin and/or nail changes. #ASH24

Predictably, after 5y of F/U the OS of cardiac stage 1-3a AL #amyloidosis is improved by adding Dara to CyBorD. This re-affirms prior landmark analyses showing depth of initial FLC response predicts subsequent survival. #ASH24